Is AGL a Buy? What to Consider in 2026
Last updated July 2026
Short answer
The bull case for AGL (AGL) rests on Margin-over-growth reset: agilon has shifted from chasing membership to prioritizing profitable contracts, exiting weaker payer relationships and markets. Revenue (TTM) is ~$5.8B. If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: agilon carries meaningful medical-cost-trend risk: because it is paid a fixed amount per member, an unexpected rise in senior utilization or unit costs can swing it back to losses, which is what drove heavy prior-year losses. Whether AGL is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.
agilon health provides a platform, capital, and technology that let community primary-care physician groups take on full financial risk for their senior patients, mostly Medicare Advantage members plus ACO REACH beneficiaries. Instead of fee-for-service billing, agilon and its partner doctors are paid a fixed amount per member and keep the difference if they keep patients healthy and out of the hospital. The model scales through long-term partnerships in individual markets, and the company reports total platform membership around 536,000, including roughly 426,000 Medicare Advantage members and 110,000 in the ACO model. The investment picture is a turnaround. After large losses in prior years (a full-year 2025 net loss of roughly $391 million), agilon has deliberately exited unprofitable payer contracts and markets, letting membership shrink to rebuild unit economics. Q1 2026 showed the early payoff: net income turned positive, adjusted EBITDA and medical margin rose sharply, and full-year revenue and profit guidance was raised. The core question for investors is whether medical-cost trends stay contained and the smaller, higher-quality book compounds into consistent profitability, or whether Medicare Advantage rate and utilization pressure erodes the improvement.
What's the case for buying AGL?
1. Margin-over-growth reset
agilon has shifted from chasing membership to prioritizing profitable contracts, exiting weaker payer relationships and markets. This shrank Medicare Advantage membership by double digits but drove medical margin and adjusted EBITDA sharply higher in early 2026. The thesis is that a smaller, cleaner book can compound into durable earnings.
2. Improving risk-adjustment and contracting
Higher estimated risk scores, CMS benchmark benefits, and newly signed full-risk payer contracts supported a raised 2026 outlook. Getting paid appropriately for the acuity of its senior patients is central to the model, and better data and contracting terms directly lift medical margin per member.
3. Multi-year value-based care tailwind
The broader shift of Medicare from fee-for-service toward value-based, capitated care is a structural tailwind for physician-enablement platforms. agilon's long-term, market-by-market partnerships with independent primary-care groups position it to add members as more physicians take on risk.
4. Path to sustained profitability
Q1 2026 delivered positive net income and a large jump in adjusted EBITDA off a low base, with guidance for full-year adjusted EBITDA turning positive. The outlook hinges on holding these gains across all four quarters rather than in a single seasonally favorable period.
What are the risks to AGL?
agilon carries meaningful medical-cost-trend risk: because it is paid a fixed amount per member, an unexpected rise in senior utilization or unit costs can swing it back to losses, which is what drove heavy prior-year losses. It is exposed to Medicare Advantage rate decisions, risk-adjustment methodology changes, and V28 model phase-in that pressure per-member revenue across the sector. The turnaround is early and depends on membership stabilizing after deliberate cuts, so profitability is not yet proven across a full year. As a small-cap with a modest share count, the stock can be volatile, and any single large market or payer contract going wrong is material. Historically it has been unprofitable on a GAAP full-year basis.
How is AGL valued? (as of July 2026)
Snapshot for AGL as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Revenue (TTM): ~$5.8B
- 2026 revenue guidance: ~$5.68B to $5.81B
- Q1 2026 revenue: ~$1.42B (down ~7% YoY)
- Q1 2026 net income: ~$49M (vs ~$12M a year earlier)
- Adjusted EBITDA guidance (2026): ~$10M to $40M
- Market cap: ~$1.8B
agilon generates billions in revenue but has historically run at a loss, posting a full-year 2025 net loss of roughly $391 million before turning to positive net income in Q1 2026. Because the company is in an early turnaround with thin projected EBITDA margins, valuation is driven more by revenue scale and the credibility of the profitability path than by current earnings multiples. Investors typically watch medical margin and membership trends rather than headline revenue growth, which is declining by design.
How do you decide if AGL is a buy?
Rather than asking whether AGL is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold AGL indirectly through an index or sector ETF before adding more.
For the full picture, see the AGL stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about AGL against your real portfolio and see your actual exposure before deciding.
The bottom line on AGL
The bottom line: AGL's story right now is Margin-over-growth reset, with revenue (ttm) at ~$5.8B. If you believe that narrative continues, the call is about sizing AGL sensibly and checking overlap with what you own; if you doubt it (the risk: agilon carries meaningful medical-cost-trend risk: because it is paid a fixed amount per member, an unexpected rise in senior utilization or unit costs can swing it back to losses, which is what drove heavy prior-year losses.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.
Build a basket around AGL with Walnut
Use AGL as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is AGL a good stock to buy right now?
+
The case for AGL right now is Margin-over-growth reset, with revenue (ttm) at ~$5.8B. If you believe that thesis holds, AGL is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is agilon carries meaningful medical-cost-trend risk: because it is paid a fixed amount per member, an unexpected rise in senior utilization or unit costs can swing it back to losses, which is what drove heavy prior-year losses. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.
What does AGL do?
+
agilon health provides a platform, capital, and technology that let community primary-care physician groups take on full financial risk for their senior patients, mostly Medicare A
What are the main risks of AGL?
+
agilon carries meaningful medical-cost-trend risk: because it is paid a fixed amount per member, an unexpected rise in senior utilization or unit costs can swing it back to losses, which is what drove heavy prior-year losses. It is exposed to Medicare Advantage rate decisions, risk-adjustment methodology changes, and V28 model phase-in that pressure per-member revenue across the sector. The turnaround is early and depends on membership stabilizing after deliberate cuts, so profitability is not yet proven across a full year. As a small-cap with a modest share count, the stock can be volatile, and any single large market or payer contract going wrong is material. Historically it has been unprofitable on a GAAP full-year basis.
What does agilon health do?
+
agilon partners with community primary-care physician groups and gives them the platform, capital, and data to manage their senior patients under value-based, capitated Medicare contracts. Instead of billing per visit, agilon and its doctors are paid a fixed amount per member and keep savings when they keep patients healthier.
Is agilon health profitable?
+
Historically no. agilon posted large GAAP losses in prior years, including a roughly $391 million net loss for full-year 2025. It reported positive net income of about $49 million in Q1 2026 and guided to positive full-year adjusted EBITDA, but sustained annual profitability is not yet proven.
Why is agilon's revenue and membership shrinking?
+
By design. Management deliberately exited unprofitable payer contracts and markets to prioritize margin over growth, which cut Medicare Advantage membership by double digits. The goal is a smaller, higher-quality book with better medical margin per member rather than maximizing top-line revenue.
How big is agilon health?
+
It generates around $5.8 billion in annual revenue and serves roughly 536,000 platform members, including about 426,000 Medicare Advantage members and 110,000 ACO model beneficiaries. As of July 2026 its market cap was around $1.8 billion, making it a small-cap relative to its revenue.
Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell AGL; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.